Package Leaflet: Information for the User
Darunavir Tillomed 400 mg film-coated tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
What is Darunavir Tillomed?
Darunavir Tillomed contains the active substance darunavir.
Darunavir is an antiretroviral medicine used to treat HIV infection. It belongs to a group of medicines called protease inhibitors. Darunavir reduces the amount of HIV in your body. This will improve your immune system and reduce the risk of diseases associated with HIV infection.
What is it used for?
Darunavir is used to treat adults and children (from 3 years of age and at least 40 kg body weight) who are infected with HIV and
Darunavir must be taken with a low dose of cobicistat or ritonavir and other HIV medicines. Your doctor will discuss with you the most suitable combination of medicines for you.
Do not take Darunavir Tillomed:
Tell your doctor about all the medicines you are taking, including those you bought without a prescription, herbal remedies, and those you have been given for other health problems.
Do not take darunavir with any of the following medicines:
If you are taking any of these medicines, consult your doctor to change to another medicine.
Medicine | Purpose of the medicine |
Avanafil | treatment of erectile dysfunction |
Astemizoleor terfenadine | treatment of allergy symptoms |
Triazolamand midazolam by mouth | to help you sleep and/or relieve anxiety |
Cisapride | treatment of stomach problems |
Colchicine(if you have kidney and/or liver problems) | treatment of gout or familial Mediterranean fever |
Lurasidone, pimozide, quetiapine, or sertindole | treatment of psychiatric problems |
Ernstome alkaloidssuch as ergotamine, dihydroergotamine, ergometrine, and methylergonovine | treatment of migraine headaches |
Amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine | treatment of certain heart rhythm disorders, for example irregular heartbeats |
Lovastatin, simvastatin, and lomitapide | to lower cholesterol levels |
Rifampicin | treatment of certain infections such as tuberculosis |
The combination of lopinavir/ritonavir | this HIV medicine belongs to the same class as darunavir |
Elbasvir/grazoprevir | treatment of hepatitis C infection |
Alfuzosin | treatment of enlarged prostate |
Sildenafil | treatment of high blood pressure in the pulmonary circulation |
Ticagrelor | to help stop platelet aggregation during treatment of patients with a history of heart attack |
Naloxegol | to treat opioid-induced constipation |
Dapoxetine | to treat premature ejaculation |
Domperidone | to treat nausea and vomiting |
Do not take darunavir with products that contain St. John's Wort (Hypericum perforatum).
Warnings and precautions
Consult your doctor, pharmacist, or nurse before you start taking darunavir.
Darunavir does not cure HIV infection. While you are taking this medicine, you may still develop infections or other illnesses associated with HIV. Keep in regular contact with your doctor.
People taking darunavir may develop skin rashes. These are usually mild and do not require treatment. However, in rare cases, skin rashes can be severe and potentially life-threatening. If you develop a skin rash or experience any of the following symptoms, please contact your doctor immediately: rash, fever, swollen lymph nodes, swelling of the face, eyelids, lips, or tongue, difficulty breathing or swallowing, or mouth sores or blisters.
Patient who take darunavir and raltegravir (for HIV infection), may present with rashes (usually mild or moderate) more frequently than patients who take either of these medicines separately.
Tell your doctor about your situation BEFORE and DURING treatment
Make sure you check the following points and tell your doctor if any of them apply to you.
Elderly population
Darunavir has only been used in a limited number of patients aged 65 years or older. If you belong to this age group, please consult your doctor to see if you can use darunavir.
Children and adolescents
Darunavir 400 mg tablets are not used in children under 3 years of age or weighing less than 40 kg.
Taking Darunavir Tillomed with other medicines
Tell your doctor or pharmacist if you are taking or have recently taken any other medicines.
Some medicines must not be takenwith darunavir. The list can be found in the section “Do not take Darunavir Tillomed with any of the following medicines:”
In most cases, darunavir can be taken with HIV medicines from other classes [e.g. NRTIs (nucleoside reverse transcriptase inhibitors), NNRTIs (non-nucleoside reverse transcriptase inhibitors), CCR5 antagonists, and FIs (fusion inhibitors)]. Darunavir has not been tested with all protease inhibitors (PIs) and must not be used with other HIV protease inhibitors. In some cases, it may be necessary to change the dose of the other medicines. Therefore, if you are taking other anti-HIV medicines, always inform your doctor and carefully follow their instructions on which medicines can be combined.
The effects of darunavir may be reduced if you take any of the following products. Tell your doctor if you are taking:
Darunavir may also affect the effects of other medicines. Your doctor may want to do some additional blood tests. Tell your doctor if you are taking:
Your doctor may want to do some additional blood tests and in certain cases, it may be necessary to adjust the dose of some medicines because when combined, the therapeutic or adverse effects of these or darunavir may be affected. Tell your doctor if you are taking:
This is nota complete list of medicines. Tell your doctor about allthe medicines you are taking.
Taking Darunavir Tillomed with food and drink
See section 3 “How to take Darunavir Tillomed.”
Pregnancy and breastfeeding
Tell your doctor immediately if you are pregnant, plan to become pregnant, or are breastfeeding. Pregnant or breastfeeding women must not take darunavir with ritonavir unless their doctor has specifically told them to do so. Pregnant or breastfeeding women must not take darunavir with cobicistat.
Due to the potential side effects in infants, women must not breastfeed if they are taking Darunavir Tillomed.
It is recommended that HIV-infected women do not breastfeed their babies to avoid transmitting the virus to them. If you are breastfeeding or thinking of breastfeeding, please consult your doctor.
Driving and using machines
Do not drive or use machines if you feel dizzy after taking Darunavir Tillomed.
Darunavir Tillomed contains sodium
This medicine contains less than 23 mg of sodium (1 mmol) per tablet, which is essentially “sodium-free”.
Follow the administration instructions of the medicine contained in this prospectus or as indicated by your doctor, pharmacist, or nurse. In case of doubt, ask your doctor, pharmacist, or nurse. Do not stop taking darunavir or cobicistat or ritonavir without consulting your doctor first, even if you feel better.
Once treatment has started, the dose or form of the dose should not be changed or treatment interrupted without consulting the doctor.
The 400-milligram darunavir tablets are used only to obtain the 800-milligram dosage once a day.
Dose for adults who have not taken antiretroviral medications before (to be determined by your doctor)
The normal dose of darunavir is 800 milligrams (2 tablets of 400 milligrams of darunavir or 1 tablet containing 800 milligrams of darunavir) once a day.
You should take darunavir every day and always in combination with 150 milligrams of cobicistat or 100 milligrams of ritonavir and with food. Darunavir does not work properly without cobicistat or ritonavir and food. Before taking darunavir and cobicistat or ritonavir, you should eat food 30 minutes before. The type of food is not important. Do not interrupt treatment with darunavir or cobicistat or ritonavir without consulting your doctor first, even if you feel better.
Instructions for adults
Dose for adults who have taken antiretroviral medications before (to be determined by your doctor)
The dose is:
Or
Please talk to your doctor about which dose is correct for you.
Dose for children from 3 years of age with ritonavir, and from 12 years of age with cobicistat, with more than 40 kilograms who have not taken antiretroviral medications before (to be determined by your child's doctor)
Dose for children from 3 years of age with ritonavir, and from 12 years of age with cobicistat, with more than 40 kilograms who have taken antiretroviral medications before (to be determined by your child's doctor)
The dose is:
Or
Please talk to your doctor about which dose is correct for you.
Instructions for children from 3 years of age with ritonavir, and from 12 years of age with cobicistat, with more than 40 kilograms
Child-resistant cap removal
The plastic bottle has a child-resistant safety cap and is opened as follows:
If you take more Darunavir Tillomed than you should
Inform your doctor, pharmacist, or nurse immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Darunavir Tillomed
If you realize within 12 hours, take the tablets immediately. Always with cobicistat or ritonavir and with food. If you realize after 12 hours, skip that dose and do the next one in the usual way. Do not take a double dose to make up for missed doses.
If you vomit after taking Darunavir Tillomed with cobicistat or ritonavir
If you vomit within 4 hoursafter taking the medication, you should take another dose of darunavir with cobicistat or ritonavir with some food as soon as possible. If you vomit when more than 4 hourshave passed since you took the medication, it is not necessary to take another dose of darunavir with cobicistat or ritonavir until the next scheduled administration time.
Contact your doctor if you are unsureof what to do if you miss a dose or if you vomit.
Do not stop taking Darunavir Tillomed without talking to your doctor first
HIV medications can make you feel better. Even if you feel better, do not stop taking darunavir. Consult your doctor first.
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
During HIV treatment, there may be an increase in weight and glucose and lipid levels in the blood. This may be partly related to the recovery of health and lifestyle, and in the case of blood lipids, sometimes to HIV medications themselves. Your doctor will monitor these changes.
Like all medications, this medication can cause side effects, although not all people experience them.
Tell your doctor if you develop any of the following side effects.
There have been reports of liver problems that can occasionally be severe. Your doctor will perform a blood test before starting darunavir. If you have a chronic infection caused by hepatitis B or C, your doctor will frequently check your blood tests since there is a greater likelihood of developing liver problems. Talk to your doctor about the signs and symptoms of liver problems. These may include yellowing of the skin and the whites of the eyes, darkening (tea color) of the urine, pale stools, nausea, vomiting, loss of appetite, or pain, discomfort, or sensitivity in the right side below your ribs.
Skin rash (more frequent when used in combination with raltegravir), itching. The skin rash is usually mild to moderate. A skin rash can also be a symptom of a rare and serious situation. It is essential that you contact your doctor if you develop a rash. Your doctor will advise you on how to control the symptoms or if you should stop taking darunavir.
Other serious side effects were diabetes (frequent) and pancreatitis (uncommon).
Very common side effects(may affect more than 1 in 10 patients):
Common side effects(may affect up to 1 in 10 patients):
Uncommon side effects(may affect up to 1 in 100 patients):
Rare side effects(may affect up to 1 in 1,000 patients):
Some side effects are typical of HIV medications that belong to the same family as darunavir. These are:
Reporting side effects
If you experience any side effects, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medications: https://www.notificarm.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date that appears on the bottle after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be thrown down the drain or into the trash. Deposit the containers and medications you no longer need in the SIGRE Point of the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medications you no longer need. This way, you will help protect the environment.
Darunavir Tillomed composition
Core of the tablet:silicified microcrystalline cellulose, crospovidone, hydroxypropylcellulose, sodium chloride, anhydrous colloidal silica, magnesium stearate, potassium polyacrylate.
Coating: Opadry II Beige 85F570070, which consists of partially hydrolyzed polyvinyl alcohol, macrogol 4000, titanium dioxide (E171), talc, yellow iron oxide (E172), red iron oxide (E172).
Appearance of the product and package contents
Beige film-coated tablet, oval, biconvex, engraved with "D" on one side and "400" on the other.
Darunavir Tillomed is available in: a white, opaque, high-density polyethylene (HDPE) plastic bottle containing 30 film-coated tablets, provided with a polypropylene (PP) cap with a child-resistant safety closure.
Package size:
Multiple package containing 60 film-coated tablets (2 packages of 30 tablets).
Marketing authorization holder and manufacturer
Marketing authorization holder
Laboratorios Tillomed Spain, S.L.U.
C/ Cardenal Marcelo Spínola 8, 1st floor, door F
28016 Madrid
Spain
Manufacturer
MIAS Pharma Limited
Suite 2, Stafford House, Strand Road
Portmarnock, Co. Dublin
Ireland
Or
Tillomed Malta Limited
Malta Life Sciences Park
LS2.01.06 Industrial Estate
San Gwann, SGN 3000,
Malta
This medication is authorized in the member states of the European Economic Area with the following names:
Germany Darunavir Tillomed 400 mg, film-coated tablets
Italy Darunavir Tillomed
Spain Darunavir Vivanta 400 mg film-coated tablets EFG
Date of the last revision of this prospectus:November 2023
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/